Comparative Pharmacology
Head-to-head clinical analysis: ABITREXATE versus PURIXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABITREXATE versus PURIXAN.
ABITREXATE vs PURIXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient, is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, inhibiting DNA synthesis, repair, and cellular replication. It also has immunosuppressive and anti-inflammatory effects via modulation of adenosine and cytokine pathways.
Purixan (mercaptopurine) is a purine analog that inhibits de novo purine synthesis by interfering with nucleotide interconversion and incorporation into DNA and RNA. It requires intracellular activation to 6-mercaptopurine ribonucleotide (6-MP ribonucleotide) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
7.5 mg orally once weekly; alternatively, 7.5 mg subcutaneously once weekly. Dose may be increased by 2.5 mg every 1-2 weeks up to 20 mg once weekly based on response and tolerability.
75 mg/kg once weekly orally; may be increased by 25 mg/kg every 2-4 weeks to a maximum of 150 mg/kg once weekly.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (mean 7.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment. Clinically, monitoring for myelosuppression is essential due to accumulation.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug and metabolites; approximately 50% as unchanged drug, 20% as 6-thiouric acid, and minor amounts as other metabolites. Biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Antimetabolite
Antimetabolite